These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 10225537)
1. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? Lipsky PE J Rheumatol Suppl; 1999 Apr; 56():25-30. PubMed ID: 10225537 [TBL] [Abstract][Full Text] [Related]
2. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms. Nasir A; Fernandez PM; Chughtai OR; Kaiser HE In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894 [TBL] [Abstract][Full Text] [Related]
3. [Biological functions of cyclooxygenase 2: control of its expression and activity]. Jacquemin C J Soc Biol; 2000; 194(3-4):189-93. PubMed ID: 11324321 [TBL] [Abstract][Full Text] [Related]
4. COX-1 and COX-2 in health and disease. Adelizzi RA J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S7-12. PubMed ID: 10643175 [TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase 2: from inflammation to carcinogenesis. Ristimäki A Novartis Found Symp; 2004; 256():215-21; discussion 221-6, 259-69. PubMed ID: 15027493 [TBL] [Abstract][Full Text] [Related]
6. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562 [TBL] [Abstract][Full Text] [Related]
7. The role of cyclooxygenases in inflammation, cancer, and development. Williams CS; Mann M; DuBois RN Oncogene; 1999 Dec; 18(55):7908-16. PubMed ID: 10630643 [TBL] [Abstract][Full Text] [Related]
8. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Geis GS J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538 [TBL] [Abstract][Full Text] [Related]
9. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063 [TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibition and the control of pain. Kiefer W; Dannhardt G Curr Opin Investig Drugs; 2002 Sep; 3(9):1348-58. PubMed ID: 12498012 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors. van der Bijl P; van der Bijl P Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700 [TBL] [Abstract][Full Text] [Related]
12. Regulation of cyclo-oxygenase-2. Stack E; DuBois RN Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041 [TBL] [Abstract][Full Text] [Related]
19. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma]. Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057 [TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust? Sanborn R; Blanke CD Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]